Evidence map›Paper›PMID 38647011›Full record

ArticleFuture oncology (London, England)2024

Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.

Günter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Silke Guenther, Barthold Deiters, Ulf Maywald, Thomas Wilke and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Günter NiegischDepartment of Urology, University Hospital & Medical Faculty of the Heinrich-Heine-University, Düsseldorf, 40225, Germany.ORCID 0000-0001-6929-8691
Marc-Oliver GrimmDepartment of Urology, University Hospital Jena, Jena, 07747, Germany.ORCID 0000-0003-3084-8654
Fraence HardtstockCytel, Berlin, 10785, Germany.ORCID 0000-0003-4698-1628
Julia KriegerCytel, Berlin, 10785, Germany.ORCID 0000-0001-5816-0611
Alexandra StarryCytel, Berlin, 10785, Germany.ORCID 0000-0003-2352-511X
Ulrike OsowskiMerck Healthcare Germany GmbH, Weiterstadt, 64331, Germany, an affiliate of Merck KGaA.
Silke GuentherMerck Healthcare KGaA, Darmstadt, 64293, Germany.
Barthold DeitersGWQ ServicePlus AG, Düsseldorf, 40549, Germany.ORCID 0000-0002-1630-8080
Ulf MaywaldDrug department, AOK PLUS, Dresden, 01058, Germany.
Thomas WilkeIPAM e.V., Wismar, 23966, Germany.ORCID 0000-0001-8932-6426
Mairead KearneyMerck Healthcare KGaA, Darmstadt, 64293, Germany.

Funding

MerckMerck (CrossRef Funder ID: 10.13039/100009945)
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Transitional CellAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleGermanyHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsUrologic Neoplasmsfirst-line treatmentmetastatic urothelial carcinomaoverall survivalprogression-free survivalreal-world treatment patternsystemic treatmenttreatment discontinuation

Identifiers

PMID38647011
PMCPMC11321406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.